[Use of domestic human insulin in patients with type I diabetes mellitus].

Twenty-five patients with type I diabetes mellitus (8 women and 7 men) aged 19 to 54 with a disease duration of 3 to 19 years were treated by Russian semisynthetic short-acting human insulin mono-H. The daily dose varied from 24 to 44 U. The drug therapeutic efficacy was assessed from the terms of attainment of carbohydrate metabolism compensation, glycosylated hemoglobin level, and changes in daily insulin requirement. Clinical safety of the drug was assessed from changes in antiinsulin antibody level, incidence and severity of hypoglycemia, absence of lipodystrophy and other adverse reactions. The drug was found effective for the treatment of patients with type I diabetes. Its hypoglycemic effect was similar to that of actrapid, a porcine insulin. Fractionated insulin therapy resulted in the majority of patients in a reduction of glycosylated hemoglobin level, of daily requirement in insulin, and of antiinsulin antibody titer.